Pro Share Advisors LLC Jounce Therapeutics, Inc. Transaction History

Pro Share Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$2.8 - $7.67 $32,155 - $88,082	-11,484 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$6.01 - $8.54 $17,627 - $25,047	-2,933 Reduced 20.34%	11,484 $78,000
Q4 2021 Feb 08, 2022	SELL	$7.11 - $9.64 $5,353 - $7,258	-753 Reduced 4.96%	14,417 $120,000
Q3 2021 Nov 12, 2021	SELL	$5.04 - $8.73 $13,023 - $22,558	-2,584 Reduced 14.55%	15,170 $113,000
Q2 2021 Aug 13, 2021	BUY	$6.58 - $10.66 $45,283 - $73,362	6,882 Added 63.3%	17,754 $121,000
Q1 2021 May 14, 2021	BUY	$6.73 - $13.87 $73,168 - $150,794	10,872 New	10,872 $112,000
Q4 2018 Feb 14, 2019	SELL	$2.69 - $6.71 $40,976 - $102,213	-15,233 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$6.5 - $8.37 $3,224 - $4,151	-496 Reduced 3.15%	15,233 $99,000
Q2 2018 Aug 13, 2018	SELL	$7.27 - $21.88 $7,488 - $22,536	-1,030 Reduced 6.15%	15,729 $120,000
Q1 2018 May 14, 2018	SELL	$13.4 - $28.4 $37,010 - $78,440	-2,762 Reduced 14.15%	16,759 $375,000
Q4 2017 Feb 14, 2018	BUY	$12.52 - $17.82 $244,402 - $347,864	19,521	19,521 $249,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Pro Share Advisors LLC with notifications on news.